Know Cancer

forgot password

Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma

Phase 2
18 Years
Not Enrolling
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma

Thank you

Trial Information

Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma


I. Determine the objective response rate in patients with unresectable malignant pleural
mesothelioma (MPM) treated with PXD101.


I. Determine the overall survival and time to progression in these patients. II. Assess the
toxicities associated with this drug in these patients. III. Perform molecular correlative
studies on tumor tissue (optional) and peripheral blood (required) and identify potential
predictive markers for response.


Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for
up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection during course 1 of treatment for biomarker correlative
studies. Fetal hemoglobin (hemoglobin F) levels are measured via reverse
transcriptase-polymerase chain reaction as a potential predictive marker for response.

After completion of study treatment, patients are followed periodically.

Inclusion Criteria:

- Histologically or cytologically confirmed malignant pleural mesothelioma (MPM) of any
of the following subtypes:

- Epithelial

- Sarcomatoid

- Mixed

- Have received only 1 prior systemic chemotherapy regimen for advanced mesothelioma

- Prior intrapleural cytotoxic agents (including bleomycin) not considered
systemic chemotherapy

- Patients who are not candidates for combination chemotherapy are eligible even
if they have not received prior chemotherapy

- Unresectable disease

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by
conventional techniques OR >= 10 mm by spiral CT scan

- The sole site of measurable disease must not be located within the radiotherapy

- No known brain metastases

- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

- Life expectancy > 3 months

- WBC >= 3,000/mm^3

- Absolute neutrophil count >= 1,500/mm^3

- Platelet count >= 100,000/mm^3

- Bilirubin normal

- AST/ALT =< 2.5 times upper limit of normal

- Creatinine normal OR creatinine clearance >= 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-barrier contraception for 1 week before,
during, and for >= 2 weeks after completion of study treatment

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to PXD101

- No symptomatic congestive heart failure

- No congestive heart failure related to primary cardiac disease

- No unstable angina pectoris

- No cardiac arrhythmia

- No condition requiring anti-arrhythmic therapy

- No uncontrolled hypertension

- No myocardial infarction within the past 6 months

- No ischemic or severe valvular heart disease

- No ongoing or active infection

- No marked baseline prolongation of QT/QTc interval

- No repeated QTc interval > 500 msec

- No long QT syndrome

- No other significant cardiovascular disease

- No other uncontrolled intercurrent illness

- No psychiatric illness or social situation that would preclude study compliance

- Recovered from prior therapy

- No prior valproic acid or other known histone deacetylase (HDAC) inhibitor

- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- More than 3 weeks since prior radiation therapy

- No concurrent medication that may cause torsade de pointes

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent investigational agents

- No other concurrent anticancer agents or therapies

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective tumor response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee

Outcome Time Frame:

Up to 3 years

Safety Issue:


Principal Investigator

Suresh Ramalingam

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beckman Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

June 2006

Completion Date:

Related Keywords:

  • Advanced Malignant Mesothelioma
  • Epithelial Mesothelioma
  • Recurrent Malignant Mesothelioma
  • Sarcomatous Mesothelioma
  • Mesothelioma



City of HopeDuarte, California  91010